Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxybutynin controlled release vaginal - Teva Pharmaceutical Industries

Drug Profile

Oxybutynin controlled release vaginal - Teva Pharmaceutical Industries

Alternative Names: DR-3001; Enhance UI; Oxybutynin transvaginal ring (TVR) - Teva

Latest Information Update: 09 Feb 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duramed Pharmaceuticals Inc
  • Developer Teva Pharmaceutical Industries
  • Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-III for Overactive bladder in USA and Canada (Vaginal)
  • 07 May 2012 Efficacy data from a phase II trial in Overactive bladder presented at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting (ACOG-2012)
  • 31 Jul 2010 Duramed completes a phase III safety extension trial (NCT00782769) in Overactive bladder in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top